InflaRx (NASDAQ:IFRX) Short Interest Update

InflaRx (NASDAQ:IFRX) was the target of a significant decline in short interest during the month of August. As of August 15th, there was short interest totalling 227,600 shares, a decline of 9.2% from the July 31st total of 250,600 shares. Based on an average daily volume of 99,000 shares, the days-to-cover ratio is presently 2.3 days.

InflaRx Trading Up 1.3 %

Shares of NASDAQ:IFRX traded up $0.02 during midday trading on Tuesday, reaching $1.61. The company had a trading volume of 57,793 shares, compared to its average volume of 176,121. The stock has a market cap of $94.80 million, a P/E ratio of -2.04 and a beta of 1.58. The company’s 50 day moving average price is $1.54 and its 200 day moving average price is $1.52. InflaRx has a 52-week low of $1.14 and a 52-week high of $4.30.

InflaRx (NASDAQ:IFRX) last released its earnings results on Thursday, August 8th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). InflaRx had a negative net margin of 44,046.09% and a negative return on equity of 47.03%. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.04 million. Research analysts forecast that InflaRx will post -0.98 EPS for the current fiscal year.

Hedge Funds Weigh In On InflaRx

An institutional investor recently raised its position in InflaRx stock. Ikarian Capital LLC grew its position in shares of InflaRx (NASDAQ:IFRX) by 2.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 704,987 shares of the company’s stock after buying an additional 16,383 shares during the period. Ikarian Capital LLC owned 1.20% of InflaRx worth $1,086,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 42.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of InflaRx in a research report on Monday, June 24th.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.